Leptomeningeal enhancement in multiple sclerosis and other neurological diseases: A systematic review and Meta-Analysis

被引:38
作者
Ineichen, Benjamin, V [1 ,2 ]
Tsagkas, Charidimos [1 ,3 ,4 ,5 ,6 ,7 ]
Absinta, Martina [8 ,9 ,10 ]
Reich, Daniel S. [1 ]
机构
[1] NINDS, Translat Neuroradiol Sect, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA
[2] Univ Zurich, Univ Hosp Zurich, Clin Neurosci Ctr, Dept Neuroradiol, Zurich, Switzerland
[3] Univ Hosp Basel, Dept Med, Neurol Clin & Policlin, Basel, Switzerland
[4] Univ Hosp Basel, Dept Clin Res, Neurol Clin & Policlin, Basel, Switzerland
[5] Univ Hosp Basel, Dept Biomed Engn, Neurol Clin & Policlin, Basel, Switzerland
[6] Univ Basel, Basel, Switzerland
[7] Univ Hosp Basel, Dept Med & Biomed Engn, Translat Imaging Neurol ThINk Basel, Basel, Switzerland
[8] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA
[9] Univ Vita Salute San Raffaele, Milan, Italy
[10] IRCCS San Raffaele Sci Inst, Neurol Unit, Milan, Italy
基金
瑞士国家科学基金会;
关键词
Multiple sclerosis; Leptomeningeal enhancement; Leptomeningeal inflammation; Magnetic resonance imaging; Systematic review; Meta-analysis; MRI FINDINGS; BRAIN; FLAIR; INFLAMMATION;
D O I
10.1016/j.nicl.2022.102939
中图分类号
R445 [影像诊断学];
学科分类号
100207 ;
摘要
Background: The lack of systematic evidence on leptomeningeal enhancement (LME) on MRI in neurological diseases, including multiple sclerosis (MS), hampers its interpretation in clinical routine and research settings. Purpose: To perform a systematic review and meta-analysis of MRI LME in MS and other neurological diseases. Materials and Methods: In a comprehensive literature search in Medline, Scopus, and Embase, out of 2292 publications, 459 records assessing LME in neurological diseases were eligible for qualitative synthesis. Of these, 135 were included in a random-effects model meta-analysis with subgroup analyses for MS. Results: Of eligible publications, 161 investigated LME in neoplastic neurological (n = 2392), 91 in neuroinfectious (n = 1890), and 75 in primary neuroinflammatory diseases (n = 4038). The LME-proportions for these disease classes were 0.47 [95%-CI: 0.37-0.57], 0.59 [95%-CI: 0.47-0.69], and 0.26 [95%-CI: 0.20-0.35], respectively. In a subgroup analysis comprising 1605 MS cases, LME proportion was 0.30 [95%-CI 0.21-0.42] with lower proportions in relapsing-remitting (0.19 [95%-CI 0.13-0.27]) compared to progressive MS (0.39 [95%-CI 0.30-0.49], p = 0.002) and higher proportions in studies imaging at 7 T (0.79 [95%-CI 0.64-0.89]) compared to lower field strengths (0.21 [95%-CI 0.15-0.29], p < 0.001). LME in MS was associated with longer disease duration (mean difference 2.2 years [95%-CI 0.2-4.2], p = 0.03), higher Expanded Disability Status Scale (mean difference 0.6 points [95%-CI 0.2-1.0], p = 0.006), higher T1 (mean difference 1.6 ml [95%-CI 0.1-3.0], p = 0.04) and T2 lesion load (mean difference 5.9 ml [95%-CI 3.2-8.6], p < 0.001), and lower cortical volume (mean difference -21.3 ml [95%-CI -34.7-7.9], p = 0.002). Conclusions: Our study provides high-grade evidence for the substantial presence of LME in MS and a comprehensive panel of other neurological diseases. Our data could facilitate differential diagnosis of LME in clinical settings. Additionally, our meta-analysis corroborates that LME is associated with key clinical and imaging features of MS.
引用
收藏
页数:18
相关论文
共 57 条
  • [1] Absinta M., 2020, CONTROVERSIAL ASS LE
  • [2] Leptomeningeal gadolinium enhancement across the spectrum of chronic neuroinflammatory diseases
    Absinta, Martina
    Cortese, Irene C. M.
    Vuolo, Luisa
    Nair, Govind
    de Alwis, Manori P.
    Ohayon, Joan
    Meani, Alessandro
    Martinelli, Vittorio
    Scotti, Roberta
    Falini, Andrea
    Smith, Bryan R.
    Nath, Avindra
    Jacobson, Steven
    Filippi, Massimo
    Reich, Daniel S.
    [J]. NEUROLOGY, 2017, 88 (15) : 1439 - 1444
  • [3] Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis
    Absinta, Martina
    Vuolo, Luisa
    Rao, Anuradha
    Nair, Govind
    Sati, Pascal
    Cortese, Irene C. M.
    Ohayon, Joan
    Fenton, Kaylan
    Reyes-Mantilla, Maria I.
    Maric, Dragan
    Calabresi, Peter A.
    Butman, John A.
    Pardo, Carlos A.
    Reich, Daniel S.
    [J]. NEUROLOGY, 2015, 85 (01) : 18 - 28
  • [4] Differentiation of Leptomeningeal and Vascular Enhancement on Post-contrast FLAIR MRI Sequence: Role in Early Detection of Infectious Meningitis
    Ahmad, Armeen
    Azad, Sheenam
    Azad, Rajiv
    [J]. JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2015, 9 (01) : TC8 - TC12
  • [5] [Anonymous], 2017, The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses
  • [6] [Anonymous], 2015, BMJ-BRIT MED J, DOI DOI 10.1136/BMJ.G7647
  • [7] Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder
    Asgari, Nasrin
    Flanagan, Eoin P.
    Fujihara, Kazuo
    Kim, Ho Jin
    Skejoe, Hanne P.
    Wuerfel, Jens
    Kuroda, Hiroshi
    Kim, Su Hyun
    Maillart, Elisabeth
    Marignier, Romain
    Pittock, Sean J.
    Paul, Friedemann
    Weinshenker, Brian G.
    [J]. NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2017, 4 (04):
  • [8] Leptomeningeal Contrast Enhancement Is Related to Focal Cortical Thinning in Relapsing-Remitting Multiple Sclerosis: A Cross-Sectional MRI Study
    Bergsland, N.
    Ramasamy, D.
    Tavazzi, E.
    Hojnacki, D.
    Weinstock-Guttman, B.
    Zivadinov, R.
    [J]. AMERICAN JOURNAL OF NEURORADIOLOGY, 2019, 40 (04) : 620 - 625
  • [9] Bhargava P., 2021, BRAIN
  • [10] Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement
    Bhargava, Pavan
    Wicken, Cassie
    Smith, Matthew D.
    Strowd, Roy E.
    Cortese, Irene
    Reich, Daniel S.
    Calabresi, Peter A.
    Mowry, Ellen M.
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 30 : 136 - 140